Vigilance States: Central Neural Pathways, Neurotransmitters and Neurohormones

Shedding Light on the Role of Neurotransmitters in the Microenvironment of Pancreatic Cancer

Pancreatic cancer (PC) is a highly lethal malignancy with a 5-year survival rate of less than 8%. The fate of PC is determined not only by the malignant behavior of the cancer cells, but also by the surrounding tumor microenvironment (TME), consisting of various cellular (cancer cells, immune cells, stromal cells, endothelial cells, and neurons) and non-cellular (cytokines, neurotransmitters, and extracellular matrix) components. The pancreatic TME has the unique characteristic of exhibiting increased neural density and altered microenvironmental concentration of neurotransmitters. The neurotransmitters, produced by both neuron and non-neuronal cells, can directly regulate the biological behavior of PC cells via binding to their corresponding receptors on tumor cells and activating the intracellular downstream signals. On the other hand, the neurotransmitters can also communicate with other cellular components such as the immune cells in the TME to promote cancer growth. In this review, we will summarize the pleiotropic effects of neurotransmitters on the initiation and progression of PC, and particularly discuss the emerging mechanisms of how neurotransmitters influence the innate and adaptive immune responses in the TME in an autocrine or paracrine manner. A better understanding of the interplay between neurotransmitters and the immune cells in the TME might facilitate the development of new effective therapies for PC.

The retinoid X receptor: a nuclear receptor that modulates the sleep-wake cycle in rats

RATIONALE

The nuclear receptor retinoid X receptor (RXR) belongs to a nuclear receptor superfamily that modulates diverse functions via homodimerization with itself or several other nuclear receptors, including PPARα. While the activation of PPARα by natural or synthetic agonists regulates the sleep-wake cycle, the role of RXR in the sleep modulation is unknown.

OBJECTIVES

We investigated the effects of bexarotene (Bexa, a RXR agonist) or UVI 3003 (UVI, a RXR antagonist) on sleep, sleep homeostasis, levels of neurochemical related to sleep modulation, and c-Fos and NeuN expression.

METHODS

The sleep-wake cycle and sleep homeostasis were analyzed after application of Bexa or UVI. Moreover, we also evaluated whether Bexa or UVI could induce effects on dopamine, serotonin, norepinephrine epinephrine, adenosine, and acetylcholine contents, collected from either the nucleus accumbens or basal forebrain. In addition, c-Fos and NeuN expression in the hypothalamus was determined after Bexa or UVI treatments.

RESULTS

Systemic application of Bexa (1 mM, i.p.) attenuated slow-wave sleep and rapid eye movement sleep. In addition, Bexa increased the levels of dopamine, serotonin, norepinephrine epinephrine, adenosine, and acetylcholine sampled from either the nucleus accumbens or basal forebrain. Moreover, Bexa blocked the sleep rebound period after total sleep deprivation, increased in the hypothalamus the expression of c-Fos, and decreased NeuN activity. Remarkably, UVI 3003 (1 mM, i.p.) induced opposite effects in sleep, sleep homeostasis, neurochemicals levels, and c-Fos and NeuN activity.

CONCLUSIONS

The administration of RXR agonist or antagonist significantly impaired the sleep-wake cycle and exerted effects on the levels of neurochemicals related to sleep modulation. Moreover, Bexa or UVI administration significantly affected c-Fos and NeuN expression in the hypothalamus. Our findings highlight the neurobiological role of RXR on sleep modulation.

Baseline Pupil Diameter Is Not a Reliable Biomarker of Subjective Sleepiness

Sleepiness is commonly seen as reflecting the basic physiological need to sleep and is associated with physiological and neurobiological changes. Subjective evaluations of sleepiness, however, are neither representative of cognitive and physical performances, nor of physiological sleepiness. Finding a simple, rapid, and objective marker of sleepiness is essential in order to prevent errors and accidents, but this has remained largely unsuccessful. The aim of this study was to determine whether the baseline pupil diameter is a physiological biomarker of sleepiness at all times of day and to isolate the regulatory components involved. Twelve healthy men (20-29 years old) participated in a 56-h experimental protocol, including a 34-h constant routine paradigm with enforced wakefulness. This protocol was used in order to eliminate the potential influence of all environmental rhythms and reveal the endogenous circadian rhythmicity of two physiological measures: sleepiness and pupil diameter. Sleepiness was assessed subjectively every hour on a computerized 10 cm visual analog scale and pupil size was recorded every 2 h with a hand-held video-pupilometer. Our results revealed that subjective sleepiness increased linearly with time awake and displayed a circadian rhythm. Baseline pupil diameter showed a linear decrease with time spent awake as well as a circadian 24-h rhythm. This is the first evidence of a circadian variation of the baseline pupil size in a highly-controlled constant routine paradigm conducted in very dim light conditions. An overall negative correlation between the size of the pupil and the subjective level of sleepiness was observed. Analyzing the contribution of the two sleep regulation components in this correlation, we further showed: (1) a negative correlation between the homeostatic sleep pressure components, (2) a negative correlation between the circadian drives only during half of the 24 hours, corresponding to 62% of the biological day and 25% of the biological night. These results highlight that, due to the dual regulation of sleepiness by the homeostatic and circadian processes, baseline pupil diameter is an index of sleepiness only at certain times and therefore cannot be used as a systematic and reliable biomarker of sleepiness.